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 ABSTRACT 
Branched chain amino acid (BCAA) metabolism occurs within the mitochondrial matrix and is 
comprised of 17 enzymes, some shared, organized into three pathways for the catabolism of 
leucine, isoleucine, and valine (LEU, ILE, and VAL respectively). However, the physical 
relationships of the various enzymes in the pathways are unknown. Diseases such as isovaleric 
academia, propionic and methylmalonic acidemias, and maple syrup urine disease are among the 
disorders caused by genetic deficiencies of BCAA metabolism.  
I examined the BCAA pathways and their physical interactions in vitro through 
proteomics analysis and in situ using stimulated emission depletion microscopy. The functional 
interactions of the pathways were measured by flux analysis with labeled LEU, ILE, and VAL in 
patient and wild type cell lines, with quantification of the labeled metabolic end-products of each 
pathway. I examined novel potential treatments for propionic acidemia patient derived cell lines, 
quantitating protein, ROS production, and mitochondrial mass response to therapeutic agents. 
My proteomic and imaging studies are consistent with the existence of one or more 
energetically favorable, metabolite-channeling BCAA super-complex(es). Flux studies 
demonstrate that the end products of LEU, ILE and VAL metabolism are generated in both wild 
type and patient derived cells lines, implying cross-talk of BCAA pathways, and a close 
proximity of shared enzymes. Additionally, I found that the end-product of ILE and VAL, 
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propionyl-CoA, does not readily enter the TCA cycle, as previously thought, while propionyl-
CoA from odd chains fats does. Finally, propionyl-CoA carboxylase (PCC) deficient cell lines 
showed improved mitochondrial function when treated with a cardiolipin binding protein that 
stabilizes the inner mitochondrial membrane in cell cultures. PCC protein amount was slightly 
increased in treated patient cells, and ROS and mitochondrial mass was significantly decreased. 
These results provide novel insight into BCAA metabolism and offer new opportunities 
for the development of therapeutic agents for their defects. Furthermore, because propionyl-CoA 
derived from odd-chain fatty acids does, in fact, readily enter the TCA cycle, results from the 
metabolic flux studies will impact public health by changing potential therapies used to replenish 
the TCA cycle intermediates for disorders of fatty acid oxidation as well as BCAA metabolism. 
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LIST OF ABBREVIATIONS 
3MCC – 3-methylcrotonyl-CoA carboxylase; including alpha and beta subunits labeled 
as MCCC1 and MCCC2 
ACAD – acyl-CoA dehydrogenase 
BCAA – branched chain amino acids 
BCKDH – branched chain alpha keto dehydrogenase complex; including alpha and beta 
subunits labeled as BCKDHA and BCKDHB 
BNGE – blue native gel electrophoresis 
BM(PEG)3 – 1,11-bis(maleimido)triethylene glycol; a cross-linker 
BSA – bovine serum albumin 
PBS – phosphate buffered saline 
DMEM – Dulbecco’s modification of Eagle’s medium 
DSA – Donkey serum albumin 
EGS – ethylene glycolbis(succinimidylsuccinate); a cross-linker 
ETC – electron transport chain 
FAO – fatty acid oxidation; FAOD – fatty acid oxidation disorders 
FBS – fetal bovine serum 
GLN - glutamine 
IBD – isobutyryl-CoA dehydrogenase 
IF – immunofluorescence 
ILE – isoleucine 
IVA – isovaleric acidemia 
IVD – isovaleryl-CoA dehydrogenase 
LCSMCC – Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-
amidocaproate); a cross-linker 
LEU - leucine 
MMA – methylmalonic acidemia 
MSUD – maple syrup urine disease 
MUT – methylmalonyl-CoA mutase 
Native-PAGE – non-denaturing gel electrophoresis 
PBB – phosphate buffered saline containing 2% BSA 
PCC – propionyl-CoA carboxylase; including alpha and beta subunits labeled as PCCA 
and PCCB 
PPA – propionic acidemia 
RT – room temperature 
SBCAD – short-branched chain acyl-CoA dehydrogenase 
SDS-PAGE – sodium dodecyl sulfate polyacrylamide gel electrophoresis 
STED – stimulated emission depletion 
Sulfo-EGS – a water-soluble version of EGS cross-linker 
TCA – tricarboxylic acid 
VAL – valine 
1.0  INTRODUCTION 
1.1 BCAA METABOLISM AND RELATED DISORDERS 
Catabolism of the essential branched chain amino acids (BCAA) leucine, isoleucine, and valine 
(LEU, ILE, and VAL, respectively) begins with transport into mitochondria, followed by 
deamination to their 2-oxo-branched chain organic acids, then oxidative decarboxylation to form 
branched chain acyl coenzyme A (CoA) products1,2. This is accomplished through a set of 
transporters and enzymes common to all three amino acids. More detail about the individual 
BCAA enzymes is reviewed below. Thereafter, the pathways diverge (Figures 1–4). Defects in 
these pathways cause 15 known metabolic disorders termed branched chain organic acidurias1,2. 
These disorders are numbered in Figure 1 below. Among the most common of these disorders 
are those of the acyl-CoA dehydrogenases (ACADs) specific to LEU, ILE, and VAL: isovaleryl-
CoA dehydrogenase (IVD), short/branched chain acyl-CoA dehydrogenase (SBCAD, also 
known as 2-methylbutyryl-CoA dehydrogenase), and isobutyryl-CoA dehydrogenase (IBD), 
respectively3. ACADs are a family of related enzymes active in fatty acid and branched chain 
amino acid oxidation that catalyze the α,β-dehydrogenation of acyl-CoA esters, transferring 
electrons to electron transferring flavoprotein (ETF)4. Biochemical and immunological studies 
have previously identified nine distinct members of this enzyme family, with each accepting a 
narrow range of substrates5,6,7,8,9,10,11,12,13,14. IVD is relatively specific towards the leucine 
metabolite isovaleryl-CoA, while SBCAD and IBD are more promiscuous, showing some 
activity towards each other’s substrates, 2-methylbutyryl-CoA and isobutyryl-CoA, respectively. 
Throughout this project, a strong emphasis will be placed on the most clinically relevant 
enzymes in the pathway: the branched chain alpha keto dehydrogenase (BCKDH) complex, the 
ACADs, 3-methylcrotonyl-CoA carboxylase (3MCC), propionyl-CoA carboxylase (PCC), and 
methylmalonyl-CoA mutase (MUT). 
 
 Figure 1. Overall BCAA metabolism. 
Enzymes of BCAA catabolism are boxed in blue and known organic acidurias are numbered. For 
the purposes of this thesis, a large emphasis will be placed on 1:IVD, 2:SBCAD, 3:IBD, 
4:3MCC, 14:PCC, and 15:MUT as they are among the most relevant clinically and historically. 
 Figure 2. LEU catabolism. 
Enzymes involved in LEU catabolism are listed in blue and their relative genes are listed in 
green (left). Alternate metabolites generated by BCAAs are listed in red (right) at their relative 
steps in the pathway. 
 Figure 3. ILE catabolism. 
Enzymes involved in ILE catabolism are listed in blue and their relative genes are listed in green 
(left). Alternate metabolites generated by BCAAs are listed in red (right) at their relative steps in 
the pathway. 
 Figure 4. VAL catabolism. 
Enzymes involved in VAL catabolism are listed in blue and their relative genes are listed in 
green (left). Alternate metabolites generated by BCAAs are listed in red (right) at their relative 
steps in the pathway. 
1.1.1 The BCKDH complex 
Deficiency of the second shared step of BCAA metabolism, the BCKDH complex, is among the 
most common disorders of the BCAA catabolic pathway, known as maple syrup urine disease 
(MSUD)15,16. MSUD results in an increased level of BCAAs as well as the accumulation of 
branched-chain alpha-ketoacids in the plasma and urine–with leucine derivatives being the 
highest–causing a pronounced odor of maple syrup. MSUD is an autosomal recessive disorder 
affecting approximately 1 in 185,000, though it is more common in the Mennonite population. 
Patients with untreated MSUD are at risk for sudden death due to recurrent metabolic crisis and 
subsequent cerebral edema caused by high levels of leucine in the brain. The BCKDH complex 
is a 4,000 kDa multimeric enzyme consisting of three catalytic domains: a thiamine 
pyrophosphate-dependent carboxylase (known as E1), encoded by two genes–BCKDHA and 
BCKDHB encoding the α and β subunits; a transacylase E2 subunit, encoded by the gene DBT 
which forms the 24-subunit core of the enzyme; and a dehydrogenase E3 subunit, encoded by 
DLD15. BCKDH activity is regulated by a specific kinase and phosphatase through a reversible 
phosphorylation/dephosphorylation mechanism.  
1.1.2 BCAA ACADs 
Inborn errors of metabolism caused by mutations in the BCAA ACADs IVD, ACADSB 
(encoding SBCAD), and ACAD8 (encoding IBD) genes involved in LEU, ILE, and VAL 
catabolism, respectively, have been extensively described, and are now identified through 
newborn screening by tandem mass spectrometry (MS/MS) in all babies born in the US1,2. The 
overall structure of these ACADs is a homotetramer, with the subunits arranged as a dimer of 
dimers. They have a similar tertiary fold consisting of an N-terminal α-helix domain, a β-sheet 
domain, and a C-terminal α-helix domain. The catalytic residue is a glutamate in all known 
ACADs.  
Isovaleric acidemia (IVA), caused by a deficiency in IVD, was the first organic acidemia 
recognized when the odor of sweaty feet that surrounded an infant with episodic encephalopathy 
was shown to be due to isovaleric acid17,18. Early literature on IVA, an autosomal recessive 
disorder, emphasized two apparent phenotypes. The first was an acute, neonatal presentation 
with patients becoming symptomatic within the first two weeks of life17,18,19,20,21,22. Patients 
appeared initially well, then developed vomiting and lethargy, progressing to coma. The second 
group presented with relatively non-specific failure to thrive and/or developmental delay 
(chronic intermittent presentation). In reality, it is now apparent that patients can fall anywhere 
on the spectrum of acute to chronic presentation and that there is probably little predictive value 
to the initial presentation23,24. Moreover, with the application of MS/MS in newborn screening, 
numerous asymptomatic patients with one recurring IVD gene mutation have been reported22.  
SBCAD deficiency has been described in a patient with dramatic metabolic 
decompensation as a newborn and significant neurologic sequela; however, it has since become 
clear that most (if not all) individuals with this deficiency remain asymptomatic24,25,26. A 
common founder mutation in ACADSB has been identified in the Chinese Hmong population26.  
IBD deficiency appears to have risk for clinical symptoms intermediate between the other 
two disorders and is characterized by high urinary loss of acylcarnitine species predisposing to 
carnitine deficiency and secondary myopathy and cardiomyopathy13,27,28,29,30. While these 
symptoms have been described in some patients, most identified with IBD deficiency through 
newborn screening have been well27,30.  
IVD shows high specificity for its substrate of LEU, while SBCAD and IBD seem to be 
more promiscuous. The Km values for IVD, IBD and SBCAD have been described for each 
purified enzyme for their substrates (Table 1). IVD appears to have the lowest Km of 1.0 µM for 
isovaleryl-CoA31.  For practical purposes, the value of the Km can be interpreted as a value 
inverse to the affinity of the substrate to the enzyme. IBD and SBCAD’s Kms are 2.6 µM and 2.7 
µM for isobutyryl-CoA and 2-methylbutyryl-CoA, respectively32,33. Additionally, IVD, IBD, and 
SBCAD can utilize each other’s substrates to a lesser extent33,34. 
 
Table 1. Comparative Kms of human BCAA ACADs (µM). 
 Isovaleryl-CoA 2-methylbutyryl-CoA Isobutyryl-CoA 
IVD 1.0 Not reported N.D. 
SBCAD N.D. 2.7 130 
IBD N.D. 18 2.6 
N.D., not detectable 
 
1.1.3 3MCC 
3MCC is the ATP-dependent carboxylase that follows IVD in the leucine pathway. The 
holoenzyme of this protein is 835 kDa and is composed of 3 heterodimers encoded by MCCC1 
(~85 kDa α subunit) and MCCC2 (~60 kDa β subunit)35. Most patients deficient for 3MCC are 
asymptomatic, though some do experience acute episodes with vomiting, acidosis, 
hypoglycemia, hypotonia, and coma with physiologic stress36. Patients experiencing these 
symptoms can be treated with protein restriction and carnitine supplementation. While the 
likelihood to develop clinical symptoms with a primary deficiency of this protein is low, the 
proximity of 3MCC to other important enzymes in the BCAA pathway, such as IVD, makes it of 
potential interest when evaluating the role of changes in a potential structural metabolic complex 
in disease and treatment development. 
1.1.4 PCC and MUT 
At the distal end of the BCAA catabolism pathway lies additional clinically relevant enzymes, 
propionyl-CoA carboxylase (PCC) and methylmalonyl-CoA mutase (MUT). PCC catalyzes the 
reversible conversion of propionyl-CoA to methylmalonyl-CoA. The PCC holoenzyme is 
composed of 6 α (PCCA) and 6 β (PCCB) subunits to create a biotin-dependent dodecamer. A 
defect in either PCCA or PCCB causes the autosomal recessive disorder propionic acidemia 
(PPA).  
Following PCC, MUT catalyzes the reversible step of methylmalonyl-CoA to the 
generation of the tricarboxylic acid (TCA) cycle intermediate, succinyl-CoA (Figure 5). MUT’s 
quarternary structure is that of a homodimer. A deficiency in MUT causes methylmalonic 
acidemia (MMA), which shares similar symptoms and severity with PPA. Patients with PPA 
experience accumulation of intermediate BCAA metabolites and a depletion of anaplerotic 
agents which can cause hyperammonemia, lethargy, vomiting, and can progress to coma or 
death37. PPA is diagnosed by elevated blood C3 in new born screening by MS/MS; however, 
patients who present at infancy and are treated early may still develop neurodevelopmental 
sequalae38. PPA is estimated to occur in 1:100,000 – 1:150,000 live births in Western 
populations. PPA also appears to be more common in certain Chinese populations, Inuit 
populations of Greenland, Amish populations, and Saudi Arabians. Unfortunately, apart from 
dramatic dietary restrictions or liver transplantation that provides partial symptomatic relief, 
there are no effective treatments or cures for PPA39. 
  
Figure 5. TCA cycle. 
Enzymes involved in BCAA metabolism are highlighted in blue boxes. Enzymes of the TCA 
cycle (also known as citric acid cycle) are in green. Note the usage of LEU, ILE, and VAL as 
precursors for cofactors or intermediates. 
1.2 TREATMENT 
1.2.1 Current treatments for BCAA organic acidurias 
In all organic acidurias, there are three therapeutic goals. The first is the prevention of metabolic 
decompensation by careful clinical observation and dietary management. This includes the 
avoidance of fasting and maintaining anabolism in times of stress (like illness). Reducing the 
natural protein in the diet for 12-24 hours may help, but additional calories to promote anabolism 
must be provided. The second goal is long term reduction of the toxic metabolite through 
restriction of dietary consumption. Reduction of the toxic metabolite is key for some organic 
acidurias, such as leucine restriction in IVA, but the proper caloric and amino acid intake to 
promote normal growth for infants and children must be considered. PPA and MMA patients 
experience a restriction of an array of amino acids in their dietary consumption: VAL, 
methionine (MET), ILE, and threonine (THR), due to their ability to generate propionyl-CoA. 
The individual contributions of the propionyl-CoA progenitors to the cellular propionyl-CoA 
pool has not been examined.  
The third goal for organic aciduria therapuetics is to enhance alternative metabolic 
pathways to produce non-toxic metabolites that can be readily and safely used or excreted. For 
example, a common treatment for organic acidurias is the addition of carnitine supplementation 
to facilitate the removal of intermediate metabolites40. However, carnitine supplementation is of 
minimal therapeutic value. This project, in theory, could have the most profound effect on the 
second and third goal, as described in the “Hypothesis and Specific Aims” section below. As 
detailed throughout this dissertation, demonstartion of a promiscuous BCAA metabolon could 
lead to a new array of potential targets for therapy, while elucidation of the differential 
contribution to the cellular propioyl-CoA pool could assist in treatment of PPA. 
1.2.2 The importance of super-complex discovery in fatty acid oxidation disorders 
Previous literature as well as work currently underway in the Vockley lab has identified the 
existence of a protein super-complex in mitochondria that encompasses the enzymes of fatty acid 
oxidation (FAO) and oxidative phosphorylation. Historically, enzymes are most often 
represented as floating free in the cellular milieu, following a “hit and run” method of 
functionality in which the product of one enzyme is released after the reaction to find the next 
enzyme for which it is a substrate. However, the individual respiratory complexes exist in the 
inner mitochondrial membrane as a super-complex composed of complexes I, III, and IV 
arranged to promote channeling of electrons, thus increasing catalytic efficiency (Figure 6)41,42. 
Disturbance of the super-complex formation has dramatic clinical effects. For example, a 
recently published paper shows the effects ACAD9 deficiency has not only on FAO disorders 
(FAOD) but on mitochondrial dysfunction in general43. Some treatments currently in clinical 
trials involve the use of a cardiolipin binding peptide, elamipretide, to stabilize the inner 
mitochondrial membrane, and therefore increase cristae folding and stabilize super-complexes44. 
 
 
Figure 6. “Hit and run” vs. super-complex models of respiratory chain protein complex architecture. 
A. A previous model for respiratory chain complexes in the inner mitochondrial membrane 
implies the release of substrate into the membrane to be found by subsequent protein complexes. 
B. The current model of respiratory chain protein complexes organized into a super-complex 
allowing smooth transitions of substrate to following enzymes. See text for biological 
importance. Not to scale. 
1.3 PUBLIC HEALTH SIGNIFICANCE 
Disorders of branched chain acyl-CoA metabolism are the most common of the organic 
acidemias identified by newborn screening through MS/MS performed on all babies in the 
United States45. Among these, defects in IVD, SBCAD, and IBD are of great clinical and 
historical importance. IVA was the first organic academia described46 and ushered in a new era 
of metabolic medicine with definition of new diseases through gas chromatography/mass 
spectrometry. Many of the disorders of BCAA metabolism are now identified through newborn 
screening and affect ~1:20,000 people combined45. Recognition of the benefit of early treatment 
in prenatally diagnosed babies with IVA played a major role in the adoption of tandem mass 
spectrometry screening of blood spots from newborn babies for metabolic disease. Newborn 
screening, in turn, has brought the field full circle, identifying a much broader spectrum of 
disease than has previously been seen in IVD deficiency, and bringing into question the clinical 
relevance of IBD and SBCAD deficiency. Better definition of these disorders is critical to 
intelligent utilization of public health resources in newborn screening, and in the development of 
appropriate treatment and follow-up schemes for patients. 
This project brings together a unique blend of basic science and clinical investigation 
experience in disorders of the branched chain amino acid catabolism pathways. This project 
combines metabolomics and proteomic studies to develop an unprecedented understanding of the 
critical functional interactions necessary for efficient metabolism of branched chain amino acids. 
These findings will in turn allow a better understanding of the cellular mechanisms that define 
clinical risk for individuals with genetic disorders of these enzymes and development of novel 
therapeutic agents for their treatment. 
1.4 HYPOTHESIS AND SPECIFIC AIMS 
The goal of this project was to characterize physical and functional interactions between BCAA 
enzymes and the clinical implications of these relationships for patients with IVA, PPA, and 
other inborn errors of BCAA metabolism. The physical relationships of the various enzymes in 
the BCAA pathways are unknown. I hypothesized that the enzymes of LEU, ILE, and VAL 
catabolism form a functional, yet fluid complex that is distinct from those active in fatty acid 
oxidation or the respiratory chain (Figure 7). To discover more about overall BCAA metabolism, 
I examined the metabolic segregation of propionyl-CoA derived from its various precursors. I 
hypothesized that there would be a differential contribution to the formation of propionyl-CoA 
from BCAA and odd chain fatty acids, which would provide insights into the development of 
novel drugs for treatment of these disorders. To directly translate this project from basic science 
to therapeutics, I tested novel treatments on PPA and MMA patient derived cell lines. Improved 
therapy may improve the lives and diets of patients with PPA or MMA. The project had three 
specific aims:  
1.4.1 Specific aim 1 
1.4.1.1 Specific aim 1a 
To employ gel electrophoresis techniques with and without chemical cross-linking to identify 
interacting partners in the BCAA catabolic pathways. A sensitive and specific MS assay was 
used to characterize the proteins captured in these experiments. I predicted that BCAA ACADs 
will interact with the universal BCKDH and with subsequent enzymes, such as 3MCC, in a fluid, 
yet functional, complex.  
 
 
Figure 7. Visual representation of hypothesis. 
Here, I am hypothesizing two possible representations of a BCAA super-complex. On the left of 
the image, I am showing that it is conceivable that the separate pathways of LEU, ILE, and VAL 
are organized into separate complexes to promote metabolic channeling. On the right, I am 
showing the possibility that all three BCAA pathway enzymes are organized into a large 
multifunctional super-complex. 
 
1.4.1.2 Specific Aim 1b 
To utilize super resolution microscopy to detect direct contact between BCAA enzymes in 
cultured cells. Stimulated emission depletion (STED) imaging was utilized to directly examine 
protein-protein interactions. Control (WT) cells were treated with antibodies specific to a 
combination of enzymes in the BCAA for fluorescent imaging. Standard confocal imaging 
allows direct visualization of co-localization at a resolution of 250-300 nm. STED, in contrast, 
allows a resolution of 60-100 nm to examine co-localization at a much more precise level. I 
predicted that BCKDH, the ACADs, and 3MCC would all demonstrate a direct interaction, 
defining a BCAA metabolon. 
1.4.2 Specific Aim 2 
1.4.2.1 Specific Aim 2a 
To characterize metabolic channeling through the BCAA pathways. Previous literature has 
shown that there is significant substrate sharing, or promiscuity, between the ACADs involved in 
BCAA metabolism. Metabolism of ILE and VAL by SBCAD and IBD suggest possible 
interactions of their catabolic pathways with each other and that of LEU. Using universally 
labeled stable isotopes and patient derived cell lines, I evaluated these interactions. Significant 
promiscuity of the ACADs and other BCAA proteins would imply geographical proximity of 
these enzymes within the mitochondria. Geographic proximity can, in turn, indicate a BCAA 
super-complex, suggesting additional options for patients with BCAA organic acidurias. 
1.4.2.2 Specific Aim 2b 
To demonstrate differential contributions to the propionyl-CoA pool derived from stable isotope 
labeled branched chain amino acid and odd chain carbon fatty acid substrates. Metabolic flux 
studies performed in collaboration with Agios Pharmaceuticals were used to examine the 
amounts of propionyl-CoA derived from ILE and VAL compared to that derived from 
heptanoate and other amino acids of interest. These studies will impact proposed anaplerotic 
therapies for FAODs and BCAA metabolism currently underway. 
1.4.3 Specific Aim 3 
To apply novel therapeutics to PPA and MMA cell lines. Patient derived fibroblast cells lines 
were grown in culture and treated with two different molecules. The first was succinate, an 
anaplerotic treatment, or a substrate that can enter the TCA cycle directly to replenish the 
metabolic blocks in disorders like PPA and MMA. I predicted that succinate would ameliorate a 
TCA deficit caused by PPA and MMA. The second treatment was a cardiolipin binding peptide, 
similar to elamipretide. Cardiolipin is a mitochondrial specific phospholipid molecule that, due 
to its shape, allows formation of the cristae by the inner mitochondrial membrane47,48. When 
oxidized in disorders of energy metabolism, mitochondria become less stable and energy 
metabolism is adversely affected. Stabilization of the inner membrane structure by the addition 
of the cardiolipin binding peptide, has been shown to increase respiratory chain super-complex 
formation and function. I predicted that treatment of PPA or MMA cell lines with a novel 
cardiolipin binding peptide would improve cellular bioenergetics. The two mentioned treatments 
were tested by Western blotting to measure protein abundance; MitoSox to measure ROS 
reduction; and MitoTracker to measure mitochondrial mass reduction. 
2.0  PROTEOMICS AND IMAGING DEFINES A NOVEL BCAA SUPER-COMPLEX 
2.1 MATERIALS AND METHODS 
Materials 
Rat liver mitochondria – 8.2 mg/mL; see preparation below 
 
PBS  – 160 g NaCl + 4 g KCl + 28.4 g Na2HPO4 + 4.8 g KH2PO4 + 1L H2O = 
20X stock; 50 mL 20X PBS stock + 950 mL H2O = 1 L 1X PBS 
 
HB buffer  – 4 mL 0.5M EDTA + 50 mL glycerol + 6 mL 1 M KH2PO4 + 94 mL 1 M 
K2HPO4 + 171.15 g sucrose + 2 L H2O 
 
HEPES  – 30 mM HEPES free acid (OmniPur; Cat#5320) + 150 mM potassium 
acetate; in H2O  
 
Cross-linkers 
BM(PEG)3  – 1,11-bis(maleimido)triethylene glycol; 
– Thermo Scientific; Cat#22337;  
– 17.8 Å hydrophilic; homobifunctional, maleimide for conjugation 
between sulfhydryl groups  
 
EGS   – ethylene glycolbis(succinimidylsuccinate) 
– Thermo Scientific; Cat#21565;  
– 16.1 Å hydrophobic; homobifunctional N-hydroxysuccinimide (NHS) 
ester  
 
LCSMCC  –Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-
amidocaproate) 
– Thermo Scientific; Cat#22362;  
– 16.2 Å, hydrophobic; heterobifunctional NHS ester and maleimide 
groups allowing conjugation of amine- and sulfhydryl-containing 
molecules  
 
 
Sulfo-EGS – ethylene glycolbis(sulfosuccinimidylsuccinate); 
– Thermo Scientific; Cat#21566;  
– 16.1 Å hydrophilic; homobifunctional N-hydroxysuccinimide ester 
 
PBST    – 1 L 1X PBS + 1 mL Tween20 (Sigma; Cat#P7949) 
 
Coomassie stain  – 0.1% R250 (BioRad; Cat#161-0400) + 7% acetic acid + 40% MeOH + 
42.9% H2O 
  
Coomassie de-stain  – 10% acetic acid + 40% MeOH + 50% H2O 
 
Digitonin  – MilliPore; Cat#300410; 1/5 ratio of sample/digitonin suspended in 
HEPES to create 4mg/mL 
 
Complete media  – 500 mL Dulbecco’s modification of Eagle’s media (DMEM) (Corning; 
Cat#10-013-CV) + 50 mL fetal bovine serum (FBS) + 5 mL L-glutamine 
+ 5 mL penicillin/streptomycin 
 
Trypsin  – Corning; Cat#25-053-CI 
 
PBB    – PBS + 2% bovine serum albumin (BSA); 2.0 g BSA + 100 mL PBS 
 
Mitochondrial isolation from rat liver 
Rat liver was extracted from sacrificed rats. The liver was then sheared into ~1 cm3 pieces and 
washed multiple times with ice cold PBS until blood was washed out. All PBS was drained, and 
sheared livers were suspended in HB buffer containing 1 mL protease inhibitor/20 g tissue. 
Samples were then finely sheared on ice using an electric homogenizer in 30 s intervals with a 5 
min rest on ice in between shearing. Samples were then centrifuged at 4,000 rpm for 5 min. The 
supernatant was transferred to another vial to centrifuge at 14,000 rpm for 15 min. The 
supernatant was discarded. Finally, the outer, light-colored pellet containing the mitochondria 
was suspended with 1 mL of HB buffer. Samples were frozen at -80 oC for future use. Protein 
concentration was calculated via DC BioRad protein concentration assay according to the 
manufacturer’s instructions. 
 
Cross-linking and sample prep 
0.5 mL rat liver mitochondria were taken and suspended in 300 µL HEPES buffer. The samples 
were then incubated with the following cross-linkers in incremental amounts: 
 
Table 2. Cross-linker testing grid of incremental concentrations. 
Final mM LCSMCC 0 mM 0.4 mM 2 mM 4 mM 
Volume µL from 10mM LCSMCC 0 µL 12 µL 60 µL 120 µL 
 
Final mM BM(PEG)3 0 mM 0.2 mM 2 mM 4 mM 
Volume µL from 20mM BM(PEG)3 0 µL 3 µL 30 µL 60 µL 
 
Cross-linkers and samples were incubated for 40 min in room temperature (RT), as per 
manufacturer’s instructions. After incubation, 15 µL of 1 M Tris-HCl pH 7.1 were added and 
incubated for 15 min at RT to stop cross-linking reaction. Samples were then combined with 
equal amounts of 2X Laemmli SDS buffer (Sigma; Cat#S3401) for 5 min at 95 oC. Samples were 
loaded into 4-15% gradient criterion SDS gel (BioRad; Cat#3450027) with pattern below: 
 
 
 
 
 
 
 
 
 
Table 3. General loading pattern for SDS-PAGE. 
Well  Description Amount Purpose 
1 Molecular marker 
(BioRad; Cat#161-
0374) 
5 µL 
Western 
2 Control 
30 µL 
3 <1mM BM(PEG)3 
4 2mM BM(PEG)3 
5 4mM BM(PEG)3 
6 <1mM LCSMCC 
7 2mM LCSMCC 
8 4mM LCSMCC 
9 Pure IVD 3 µL 
10 Molecular marker 5 µL 
Staining 
11 Control 
30 µL 
12 <1mM BM(PEG)3 
13 2mM BM(PEG)3 
14 4mM BM(PEG)3 
15 <1mM LCSMCC 
16 2mM LCSMCC 
17 4mM LCSMCC 
18 Pure IVD 3 µL 
 
Western blotting 
The gel was run for 2 hrs at RT and 80V constant. The gel was transferred to a PVDF membrane 
for 35 min at 0.3 A constant. The western membrane was blocked overnight in 10% dry milk in 
PBST at 4 oC or for 40 min at RT, washed briefly with PBST, and then twice again with PBST 
for 5 min each at RT. The membrane was then incubated with a dilution of 1:300 primary 
antibody in 1% milk in PBST for 1 hr at RT or overnight at 4 oC. Commercial antibodies were 
used according to manufacturer’s instructions/suggestions. The membrane was washed 3X with 
PBST for 5 min each at RT, incubated with a dilution of 1:2000 goat-anti-rabbit/mouse HRP 
conjugate (BioRad; Cat#170-6515) secondary antibody in 1% milk protein in PBST for 1 hr at 
RT. The membrane was washed 3X with PBST for 5 min each, then incubated with 3 mL Pierce 
ECL western blot substrate (Thermo Scientific; Cat#32106) without prior mixing. Finally, the 
membrane was briefly dried for 5 min in a fume hood. X-ray film was placed on membrane in 
dark room for 1 – 5 min, or as needed to obtain clear picture after development. 
 
Table 4. Antibodies used for Western blotting. 
Antigen Source Dilution Clonality 
BCKDHB Mouse 1:200 Monoclonal 
IBD Mouse 1:100 Monoclonal 
IVD Rabbit 1:300 Polyclonal 
MCCC2 Rabbit 1:200 Polyclonal 
MUT Mouse 1:100 Monoclonal 
VDAC1 Mouse 1:100 Monoclonal 
 
Whole protein stain 
The gel was placed in staining solution containing R250 for no more than 30 min. Gel was then 
de-stained for 30 min. The de-stain was removed, replaced, and de-stained for another hour. If 
banding patterns remained unclear, the de-stain was removed and replaced once again and left to 
de-stain overnight at RT. For best imaging quality, the gel was left to rehydrate in water 
overnight at RT. 
 
Proteomic analysis 
Bands of interest were identified from western blots and cut from the de-stained gel and sent to 
the University of Pittsburgh MS Proteomics Core Facility. An in-gel reduction alkylation trypsin 
digestion was applied to samples and the extracted tryptic peptides were analyzed using liquid 
chromatography tandem mass spectrometry (LC-MS/MS) followed by database searching to 
obtain amino acid sequence49,50,51. 
 
 
2D gel electrophoresis 
For a two-dimensional gel, first a blue native-PAGE (BNGE) protocol was run. To begin BNGE, 
rat liver mitochondria samples were prepared as above and centrifuged at 5,000 rpm for 10 min. 
While centrifugation was taking place, a digitonin/HEPES master mix was made and incubated 
at 95 oC for 5 min to dissolve solution. The digitonin mixture was placed on ice for at least 20 
min. The master solution was added to the samples to give a 1/5 ratio of protein/digitonin and a 4 
mg/mL protein concentration. The samples were incubated on ice for an additional 30 min. 
Coomassie blue stain was added to samples at a 1:20 – 1:30 dilution and re-suspended by pipette. 
Samples were centrifuged at 17,000 rpm for 1 hr at 4 oC. Supernatants were transferred to new 
vials carefully so as to not disturb the pellets. Pellets were discarded. Samples were stored in -80 
oC until used. Samples were loaded onto a 3-12%, 10-well bis-tris gel (Native-PAGE; Thermo 
Scientific; Cat#BN1001BOX). The gel was run at 80 V constant for 4-5 hrs at 4 oC, then stained 
with R250 Coomassie stain for 15 min, and de-stained for 30 min, 1 hr, or overnight at RT when 
necessary as described above.  
When the Native-PAGE gel was fully de-stained, the lanes were cut and submerged in 
2X Laemmli buffer for 1 hr in RT in a fume hood. The lanes were then washed with 
tris/glycine/SDS gel running buffer (National Diagnostics; Cat#EC-870) until the buffer read a 
pH of 7 (usually about 5 min washes). In order for the gel strips to be placed on a Prep-+2 SDS-
PAGE gel, they were briefly dried under in a fume hood for 5 min. The gel strips were carefully 
placed into the large well of the Prep-+2 SDS-PAGE gel and the gel was run as above at 80 V 
constant for approximately 2 hr. The gel was transferred to a membrane, and the membrane 
stained with appropriate antibodies as indicated in the results. 
 
Immunofluorescence 
Control, wild-type, patient derived fibroblast, or HEPG2 cells were grown in culture with 
complete media changed every 48 hrs. Fibroblast cells are isolated from an 8-year-old male with 
a passage of 2-10. Cells were grown to 90% confluence and seeded onto coverslips by 
trypsinzation. To trypsinize cells in a T175 flask: the media was removed, the flask of cells was 
washed with 10 mL PBS, and ~2.5 mL trypsin was added for 5 min in 37 oC/5.0% CO2. 10 mL 
DMEM was then added to stop reaction of trypsin. Viable cells were counted by saving 1 mL of 
cells/trypsin/media and by using a Beckman Coulter Life Sciences Vi-Cell counter. Slide 
coverslips were exposed to UV light for at least 15 min, placed into a 12-well plate, coated with 
poly-L-lysine for 5 min at RT, and allowed to dry under a class II type A2 biosafety cabinet for 
an additional 15 min. The cells were seeded at approximately 50,000 viable cells/well to generate 
a monolayer and grown overnight at 37 oC with 5.0% CO2. The media was removed, and 3 brief 
washes of PBS followed. The cells were fixed using 2% paraformaldehyde in PBS for 15 min at 
RT and washed 2X in PBS. Samples were then stored in 4 oC for a maximum 6 months 
submerged in PBS. Otherwise, the cells were permeabilized with 0.1% Triton x-100 made in 
PBS for 15 min. The samples were washed 3X with PBS, followed by 5X washes with PBB. The 
samples were blocked using 5% donkey serum albumin (DSA) in PBB for 45 min at RT then 
washed 5X with PBB. For the primary antibodies solution, commercial antibodies were diluted 
to 2 µg/mL in PBB. Two antibodies could be added to the same solution provided they were 
from different host species (i.e. rabbit and mouse). Before applying primary antibodies to the 
cells, solution was vortexed, centrifuged at 10-12K rpm for 5 min, and only the solution from the 
top of the vial was used. The coverslips were incubated for 1 hr at RT or overnight at 4 oC. 
Again, cells were washed 5X with PBB. For the secondary antibodies solution, AlexaFluor 555 
and 647 were diluted 1:2000 in in PBB. From this step forward, efforts were made to keep 
antibody solutions and samples in dark conditions. Antibody dilution was vortexed, centrifuged 
at 10-12K rpm for 5 min, and the bottom of the vial was avoided. The secondary antibodies were 
added in tandem. The cells were incubated for 1 hr at RT, washed 5X with PBB followed by 5X 
washes with PBS, the stained with DAPI (life Technologies; Cat#1802093) adding 2 drops/mL 
of PBS to the monolayers. Coverslips were incubated for 5 min at RT with the DAPI stain, then 
washed 3X with PBS. Finally, coverslips were mounted on clean microscope slides with Prolong 
Diamond (Thermo Scientific; Cat#1858790) with the cells facing down, avoiding any air 
bubbles. Fluorophores are brightest and therefore highest quality after 5 days after exposure to 
Prolong Diamond and are stable up to 3 months in 4 oC. 
 
Table 5. Antibodies used for imaging. 
Antigen Source Dilution Clonality 
VLCAD Mouse 1:50 Monoclonal 
HADHA Rabbit 1:500 Monoclonal 
IVD Mouse 1:100 Monoclonal 
MCCC2 Rabbit 2 µg/mL Polyclonal 
ACADSB Rabbit 2 µg/mL Polyclonal 
ATP5B Mouse 1:50 Monoclonal 
TOM20 Rabbit 2 µg/mL Polyclonal 
 
STED imaging 
STED imaging was carried out in collaboration with the University of Pittsburgh Center for 
Biological Imaging (CBI). In brief, STED imaging works by simultaneously exciting a particular 
fluorophore and dampening the surrounding signal with incident photons52,53,54. To achieve the 
large number of incident photons to selectively deplete the surrounding signal, a high intensity 
laser must be used. This has positive and negative effects. The higher intensity laser forces the 
photons to relax at a higher vibrational state, meaning the original emission (as seen in traditional 
confocal microscopy) can effectively be ignored giving a cleaner signal. However, the high 
intensity lasers can lead to photobleaching, which can be minimized by increasing antibody 
concentration and therefore fluorescent signal. As opposed to other super-resolution microscopy 
(such as FRET), STED lasers will excited two separate fluorophores for direct imaging of 
protein-protein co-localization at a resolution of 60-100 nm. To put this in perspective, confocal 
imaging will consistently show co-localization with confidence at a resolution of 250-300 nm. 
As a baseline for mitochondrial imaging, FAO enzymes known by the Vockley lab to co-localize 
were imaged first in fibroblast cells.  
2.2 SPECIFIC AIM 1: RESULTS 
2.2.1 BCAA enzymes co-migrate on a denaturing gel 
To examine the physical relationships of the enzymes of BCAA metabolism, rat liver 
mitochondria were isolated and incubated with various types and concentrations of cross-linking 
agents (see methods for details on cross-linkers used). Treated samples were run on SDS-PAGE 
gels for approximately 2 hr at 80 V constant power. The gels were then transferred to a PVDF 
membrane for western blot analysis. The western blots were performed using a variety of 
monoclonal and polyclonal antibodies against BCAA metabolism protein subunits from 
commercial resources to stain the membranes. After many iterations of this process with 
different cross-linkers and antibodies, a consistent pattern emerged. Figure 8 shows a few 
representative examples of these experiments. In these gels, the red arrows identify consistently 
seen immunoreactive bands at a higher molecular mass than expected for each protein were it 
migrating separately from other proteins. These high molecular mass bands were only present in 
cross-linked conditions, and they increased in intensity as the concentration of the cross-linking 
increased as seen in the MCCC2 Western blot in Figure 8. The consistent bands were located just 
above the 250 kDa molecular weight marker (hereafter referred to as the ~300 kDa band). This 
band migrates at a position that is too large to be the monomer of any of enzymes to which the 
antisera used in the experiment was raised. A second consistent band appeared at a position just 
entering the gel (hereafter referred to as the >500 kDa band). It also was only present in cross-
linking conditions. This band must represent a protein complex so large that it does not readily 
enter the denaturing SDS gel. Meanwhile, the monomer ACAD size of ~40 kDa was visible in 
all lanes with varying cross-linker concentration. In the IVD blot seen in Figure 8, as an 
example, several findings are notable. The control lane contains bands at 40, 80, and 160 kDa, 
representing the monomer, dimer, and holoenzyme of a typical BCAA ACAD. As there was also 
a significant amount of background signal on the blot, the higher molecular mass bands (~300 
and 500 kDa) were excised and analyzed by mass spectrometry analysis at the University of 
Pittsburgh Mass Spectrometry core facility in order to unequivocally identify the presence of 
IVD or other BCAA proteins. Proteins in the BCAA metabolic pathway were catalogued as 
described for Figure 10.  
 
 Figure 8. Western blotting results. 
Extracts of BM(PEG)3 cross-linked liver mitochondria were separated on SDS-PAGE gels, 
transferred to nitrocellulose membranes, and visualized with antibodies as listed at the top of 
each gel section. The red arrows to the right identify bands that were consistent across multiple 
repetition of gels. The migration of BioRad Precision Plus Dual Color Protein Standard 
molecular mass markers is shown to the left of the gel. The enzyme monomer size is shown by 
an asterisk to the right of each membrane. Upper and lower limits of cross-linker concentration 
are defined by the manufacturer as 0.2 mM – 4 mM. 
 
In these experiments, rat liver mitochondria were isolated, treated with an 18 Å cross-
linker which showed the clearest and most consistent banding in the ~300 kDa and >500 kDa 
region of the gels. A non-cross-linked purified IVD was run alongside the gel as a control. The 
samples were separated by SDS-PAGE, the gel was stained with Coomassie blue to visualize all 
proteins, and bands from the gel were excised as shown in Figure 9 for analysis by mass 
spectrometry. Figure 10 shows the proteins identified. Though Figure 10 shows BCAA protein 
subunits only, the exhaustive list of proteins identified by MS is available upon request. 
 
 Figure 9. Whole protein stain of SDS-PAGE gel. 
The samples loaded were C = control; X-L = cross-link; IVD = purified IVD. The lower and 
upper limits of the cross-linker were defined by manufacturer’s instructions as 0, 0.2 mM, 2 mM, 
and 4 mM BM(PEG)3 in lanes 2-5, respectively. The ~300 kDa band, >500 kDa band, and the 40 
kDa band, shown in a red box were excised and analyzed by mass spectrometry. Molecular mass 
markers are listed on the left. 
 
 Figure 10. Heat map of BCAA mitochondrial proteins identified in gel slices by MS. 
The quantities in each cell of this map represent the quantitative value of each protein 
normalized to the entire spectra, as provided by the MS facility. The individual quantities from 
each gel slice isolated in Figure 9 are shown. The key at the bottom of the figure shows that 
darker green represents higher spectral counts of BCAA protein subunit found in each band; a 
quantitative value of 0.1 – 4.0 is shown in the palest green, while a quantitative value of 20+ is 
shown in the darkest green. Cross-linked gel slices show a much higher abundance of BCAA 
protein subunits than their non-cross-linked counterparts. Pure IVD was run alongside the gel 
from Figure 9 and analyzed via MS as a control. 
 
The mass spectrometry results clearly show a difference between control rat liver 
mitochondria versus cross-linked rat liver mitochondria. The >500 kDa and ~300 kDa bands 
contain a significant number of BCAA proteins in the cross-link samples, but not from control. 
In contrast, BCAA proteins appears in both control and cross-link lanes in the 40 kDa 
“monomer-sized” band but with much different quantities. Thus, cross-linking of mitochondria 
prior to separation leads to their migration in higher molecular mass positions on the gel. As seen 
in Figure 10, there is dramatic prevalence of BCAA subunits in the higher molecular weight 
bands in cross-linked vs control mitochondria. These results are consistent with the presence of 
high molecular mass protein complexes in mitochondria that contain multiple proteins involved 
in BCAA metabolism, suggesting that these proteins form a metabolon that promotes metabolic 
channeling. Still, we are unable to determine which proteins are binding to which. IVD, for 
example, at ~300 kDa must represent more than the holoenzyme by itself. The ~300 kDa band 
could represent the IVD holoenzyme plus a binding partner, but this partner is not likely MCCC2 
as MCCC2 forms a stable hexamer of ~300 kDa by itself. It is more likely that IVD is binding to 
members of the BCKDH complex (BCKDHA, BCKDHB, DBT, or DLD) at the ~300 kDa band 
and the presence of MCCC2 in the ~300 kDa band is due to its own hexamer formation. The 
>500 kDa band could represent the BCKDH complex, IVD, and MCCC, but it remains unclear 
by MS identification alone if these proteins are cross-linking to one another.  
2.2.2 Enzymes of the LEU pathway co-migrate in two-dimensional gel analysis 
Next, 2-dimensional (2D) gel electrophoresis was performed with rat liver mitochondria 
prepared with and without cross-linker. The cross-linker EGS was used in this experiment due to 
its ability to be chemically cleaved and restore the individual molecular masses of proteins. 
Digitonin treated samples were first separated in a non-denaturing gel in cold conditions for 4.5 
hrs at 80 V constant. The gel was then stained with Coomassie blue, and the gel lanes were 
excised and submerged in Laemmli buffer. Finally, the gel lanes were washed, placed 
horizontally in a denaturing SDS-PAGE gel, and run for second dimension separation. The SDS-
PAGE gels were then transferred to a PVDF membrane and stained with antibodies to the first 
three enzymes of the LEU pathway. Results are shown in Figure 11. Here, it is clear that the 
Western blot identifies BCAA metabolic proteins in higher molecular mass forms than expected 
for isolated proteins. This high molecular mass form is apparent only in cross-linked sections of 
the 2D gels. Superimposition of the three gels demonstrates that BCKDHB, IVD, and MCCC2 
are all contained in nearly identical positions in higher molecular mass regions of the native gel. 
These positions are well above the molecular mass of the individual proteins when mitochondria 
are treated with a cross-linking agent. These results are again consistent with the presence of a 
macromolecular complex in mitochondria containing multiple BCAA metabolic proteins. 
 
 
Figure 11. 2D results. 
Gel slices from the native gel (first dimension) are shown across the top of the second 
dimension. The top of the gel, or the higher molecular weight in the first dimension is located on 
the far left and far right of the 2D blot as indicated by the arrows at the top of the blots. Note also 
that the native gel slices were cut off at 5 cm to fit in the 2D SDS gel, resulting in little or no 
stain in the control sections of the Western blots. The center of the gel is marked with a dashed 
black line. 
 
2.2.3 Direct Imaging of LEU pathway proteins using STED confirms new model of BCAA 
super-complex 
To characterize directly the potential interactions of BCAA metabolic enzymes, imaging 
experiments of fibroblast cells were performed using confocal and STED microscopy. Wild type 
fibroblast cell lines were grown to confluence in T175 flasks, seeded onto glass cover slides as a 
monolayer, and fixed after 24 hrs for analysis. The slides were incubated with primary antibodies 
of two proteins produced in different species. For example, a mouse and a rabbit antibody were 
used in tandem. Next, the cells were treated with secondary antibodies specific for each primary 
antibody conjugated to fluorophores AlexaFluor 555 and AlexaFluor 647. Confocal and STED 
images were captured with the assistance of the University of Pittsburgh’s Center for Biological 
Imaging. As a positive control, antibodies to fatty acid oxidation proteins were first used, 
previously shown by the Vockley lab to directly interact with each other and the respiratory 
chain, forming a multifunctional super-complex within the mitochondria. Figure 12 shows, 
confocal microscopy of cells stained with antibodies to the HADHA protein, the alpha subunit of 
the mitochondrial fatty acid oxidation trifunctional protein (shown in red), and VLCAD 
antibodies, an ACAD responsible for catalyzing the first intra-mitochondrial step of fatty acid 
oxidation for long chain substrates (shown in green). The two proteins are seen to co-localize 
(yellow in merged images). While confocal microscopy demonstrates localization in subcellular 
compartments, its resolution is only ~200 nm at its best. In contrast, STED technology captures 
images with a pixel size of 20 nm, implying co-localization at a level of ~60 nm. To put this in 
perspective, a typical mitochondrion is approximately 1-2 µm in diameter. Another method of 
super-resolution microscopy, Forster resonance energy transfer (FRET), will show co-
localization of 8-10 nm; however, this technique yields a higher rate of false negative results than 
STED. 
 
 
Figure 12. Typical confocal microscopy imaging of FAO enzymes. 
Top row: DAPI, or nuclear stain, is shown in blue; staining with a VLCAD antibody is shown in 
green; and staining with an HADHA antibody is shown in red. Bottom row: merged 
combinations. Significant co-localization is shown in yellow. Co-localization can be implied at a 
resolution of ~200nm. 
 
Figures 13 and 14 show results of STED imaging. The yellow merged signal indicates 
that HADHA (of TFP) and VLCAD are close enough to be physically interacting. Figure 15 
shows a negative control using antibodies for TOM20 (an outer mitochondrial membrane 
protein) and ATP5B (an inner mitochondrial membrane protein). As expected, these protein 
subunits show no co-localization at STED resolution.  
 
 
Figure 13. STED microscopy image example using FAO enzymes. 
Top row: DAPI, or nuclear stain, is shown in blue; VLCAD is shown in green; and HADHA is 
shown in red. Bottom row: all merged combinations. Significant co-localization is shown in 
yellow. Co-localization can be implied at a resolution of <60nm. 
 
 Figure 14. Merged images of FAO enzymes co-localizing using STED. 
Following the same color scheme as in Figures 12 and 13, a significant amount of yellow 
indicated significant co-localization between TFP and VLCAD at a resolution of <60 nm using 
STED. 
 
 Figure 15. Negative control stain for STED imaging. 
DAPI shown in blue; ATPB5 (inner mitochondrial membrane bound protein) shown in green; 
TOM20 (outer mitochondrial membrane bound protein) shown in red. Little to no yellow is seen 
in the final merged images. 
 
Because fibroblast cells have a relatively sparse number of mitochondria, HEPG2 cells 
were instead used for STED imaging to assess BCAA protein interactions. Cells were seeded as 
a monolayer on a glass cover slide and imaged with a variety of antibodies to BCAA metabolic 
proteins. In all cases, as a control, the same protocol was carried out but without the primary 
antibody so that background fluorescence measurements could be taken. Note that not all 
commercially available antibodies were suitable for STED imaging. Therefore, all combinations 
of BCAA subunits could not be tested. Antibodies to IVD and MCCC2 (Figure 16) show co-
localization of these proteins involved in consecutive steps in the LEU degradative pathway. 
Three-dimensional reconstruction videos of these images are available online. These results are 
consistent with the findings obtained in Specific Aim 1a. Next, IVD and SBCAD antibodies 
were used for staining (Figure 17). This combination of antisera shows little to no co-
localization, again consistent with earlier results. In the proteomic results above, IVD is present 
in high molecular weight bands; however, SBCAD does not co-migrate with IVD on a gel. 
Together, these results suggest that proteins of the LEU degradative pathway interact, but that 
they do not interact with those of the ILE pathway.   
  
 
Figure 16. IVD and 3MCC show co-localization using STED. 
DAPI is shown in blue; MCCC2 is shown in green; IVD is shown in red. Upon close 
examination of the bottom right merged images, one can see many instances of co-localization 
between the two enzymes of the LEU degradative pathway. The mitochondrial architecture is 
visible at a resolution of <60 nm. 
 
 Figure 17. IVD and SBCAD do not show co-localization using STED imaging. 
DAPI is shown in blue; is SBCAD shown in green; is IVD shown in red. Upon close inspection, 
little yellow is seen in the final merged images. A comparison of the individual images at the top 
reveals that these two ACADs are seen in different locations in the mitochondria. Resolution of 
<60 nm. 
2.3 DISCUSSION 
The cellular cross linking and western blot findings suggest that some of the BCAA enzymes 
interact to form a protein complex. Such a complex could promote metabolic channeling. 
Proteomics experiments with mass spectrometry supports the western results since multiple 
proteins involved with the BCAA metabolic pathways were identified in higher molecular bands 
after cross-linking. Figure 18 summarizes the proteins found in high molecular mass bands 
mapped onto the BCAA catabolic pathway. Here, the difference between the cross-linked and 
control samples is clear, with many more BCAA metabolic proteins identified in cross linked 
samples. As noted briefly above, these findings alone do not differentiate between a common 
complex encompassing all BCAA pathways or individual complexes for each BCAA pathway. 
However, the STED results show that IVD and 3MCC interact with each other, while IVD and 
SBCAD do not, suggesting that the enzymes for the LEU and ILE pathways are in separate 
complexes.  
Of note, in MS studies IVD is found as a lower molecular mass monomer without cross-
linking, and in higher molecular mass complexes with cross-linking. However, SBCAD (noted 
as its gene name ACADSB in Figure 10 above) is not identified as participating in a larger 
complex. Additionally, IBD is not identified at all through MS analysis, a finding that requires 
additional study to understand.  
One major question about the clinical significance of genetic disorders of the branched 
chain ACADs is not answered by these studies. IVA is the most severe of the three deficiencies, 
while SBCAD deficiency is asymptomatic and IBD deficiency is nearly so; however, the reason 
for this difference is unclear. One possibility is that isovaleryl-CoA and its alternative 
metabolites are more toxic than those of 2-methylbutyryl- and isobutyryl-CoA. In this case, 
metabolic channeling would have nothing to do with the phenotype of each disease. In contrast, 
it may be that enzymes that can alternatively metabolize substrates accumulating to blunt their 
toxicity. In this scenario, one would expect that these enzymes would need to be physically in 
proximity to the mutant’s enzyme, otherwise, the concentration of the accumulating metabolite 
would not reach a high enough level to be used as an alternative substrate by another enzyme. 
My results show that IVD and SBCAD do not interact, thus potentially explaining the relatively 
severe symptoms seen in IVA. In addition, isovaleryl-CoA is not utilized by IBD and SBCAD. 
In contrast, IBD and SBCAD utilize each other’s substrates, and if they interact, then the local 
concentration of each blocked metabolite would become high enough to allow it to be utilized by 
the other enzyme. Additional STED experiments will be necessary to evaluate this possibility.  
 
 
Figure 18. Mapped BCAA proteins based on proteomic and imaging results. 
The presence of BCAA proteins as seen in my proteomic studies are mapped to the BCAA 
catabolic pathway. The left shows the lack of protein subunits observed at high molecular mass 
in control gel slices, while the right pathway maps the BCAA subunits observed in gel slices that 
have been exposed to chemical cross-linking. Filled boxes of blue or orange indicate the 
holoenzyme is present and the light shaded boxes indicate only a subunit of the holoenzyme was 
detected via MS. 
 
Co-localization of IVD and 3MCC in a protein complex could have significant 
implications for therapy of both disorders. Molecules that stabilize such a macro molecular 
complex could improve residual activity of a mutant enzyme and increase flux through the 
pathway. Alternatively, developing methods to shunt the metabolites to another pathway with an 
overlap in substrate specificity would decrease accumulation of the abnormal metabolite and 
reduce its toxicity. Thus, additional experiments to explore the physical relationships of the 
BCAA pathway enzymes will be of interest. 
 
3.0  A BCAA SUPER-COMPLEX AFFECTS METABOLIC FLUX 
3.1 MATERIALS AND METHODS 
Materials 
Growth media  – 500 mL DMEM + 5% (25 mL) dialyzed FBS + 5 mL L-glutamine + 5 
mL penicillin/streptomycin 
 
Labeled media  – 100 mL growth media + 50% isotope enrichment:  
 
LEU  – 10.9 mg 13C6,15N LEU + 10.5 mg ILE + 9.4 mg VAL; Cambridge 
Isotopes; Cat#CNLM-281-H-0.1 
ILE  – 10.9 mg LEU + 10.5 mg 13C6,15N ILE + 9.4 mg VAL; Cambridge 
Isotopes; Cat#CNLM-561-H-0.1 
VAL  – 10.9 mg LEU + 10.5 mg ILE + 9.4 mg 13C6,15N VAL; Cambridge 
Isotopes; Cat#CNLM-442-H-0.25 
Heptanoate  – 6 µL 5,6,7-13C3 heptanoate; Aldrich; Cat#606499-0.10G 
MET   – 7.7 mg 13C5 MET; Cambridge Isotopes; Cat#CLM-893-H-0.05 
THR   – 9.5 mg 13C4 THR; Cambridge Isotopes; Cat#CLM-2261-0.1 
GLN  – 7.65 mg 13C5 GLN (Cambridge Isotopes; Cat#CNLM-1275-H-0.1) in 
100 mL RPMI media containing no L-glutamine (Corning; Cat#15-040-
CV) 
 
Extraction buffer  – 80 mL MeOH + 20 mL H2O (HPLC grade) 
 
Ammonium carbonate – 7.2 g ammonium carbonate + 1 L H2O; pH to 7.5 with acetic acid 
 
Time points   – 0, 10, 30, 60, and 180 min  
Table 6. Characteristics of control and patient derived fibroblast cell lines tested. 
 Identifier Phenotype Gene 
affected 
Genetic 
mutation 
Protein 
change 
Passage 
range 
Available 
patient 
characteristics 
1 Fb554 Wild type N/A 5-10 8 yrs old, male 
2 Fb118 IVA IVD 149G>C 21R>P 6-10 10 days old, 
consanguineous 
parents 
3 Fb482 IBD 
deficiency 
ACAD8 455T>C 152M>T 2-10  
4 Fb589 SBCAD 
deficiency 
ACADSB 443C>T 148T>I 2-10 Female 
5 Fb860 MSUD Unknown 2-7  
6 Fb861 PPA PCCA Unknown 2-10  
7 Fb858 MMA MUT Unknown 12-15  
 
 
Stable isotope labeling 
WT and organic aciduria patient derived fibroblast cell lines were obtained and grown in T175 
culture flasks until 90% confluence. On day 1 of the protocol, cells were trypsinized, counted, 
and seeded at approximately 150,000 cells/well of three 6-well plates (Table 7). On day 2, 
complete DMEM media was removed and cells were fed with DMEM media containing 5% 
dialyzed FBS. On day 3, the labeling studies were performed. First, 1 hr prior to the first 180 min 
time point, the media in the T175 flask was refreshed with 5% dialyzed FBS DMEM. Before the 
first 180 min time point, 100 mL fresh media containing uniformly 13C,15N-labeled amino acid 
and 500 mL fresh ammonium carbonate wash were made. Both solutions were placed in a 37 oC 
water bath to completely dissolve the substrates. The labeled media was vacuum filtered. Growth 
media was aspirated from wells for the first time point (180 min). The wells were washed with 
~2 mL ammonium carbonate for <1 min and aspirated fully. 2.5 mL labeled media was added to 
cells for first time point and incubated in a 37 oC/5.0% CO2 incubator. Wash and incubation for 
each time point was repeated at 60, 30, and 10 min time points. No label was added to the 0 min 
time point. In between time points, cell counts in triplicate wells were measured with a Vi-Cell 
instrument. At the end of all time points, all wells were briefly washed with ammonium 
carbonate. Extraction buffer was added in a 1 µL/1,000 cell ratio and incubated on dry ice or -80 
oC for 10 min. The extraction buffer was removed and saved in labeled Eppendorf tubes, with 
special attention to obtain as much extract as possible. Samples were centrifuged at 12,000 rpm 
for 10 min in 4 oC. Supernatant of samples were then transferred to a 96-well plate (Table 8). 
Finally, the wells were dried in a vacuum centrifuge (>1 hr). The plate was wrapped in Parafilm, 
clearly labeled with date, experiment, and name, and stored in -80 oC.  
 
Table 7. 6-well plate layout for metabolic flux studies. 
 1 2 3 
A Time point 180,  
Time point 30,  
Time point 0 
Time point 180,  
Time point 30,  
Time point 0 
Time point 180,  
Time point 30,  
Time point 0 
B Time point 60,  
Time point 10,  
Cells to count 
Time point 60,  
Time point 10,  
Cells to count 
Time point 60,  
Time point 10,  
Cells to count 
 
 
 
 
 
 
 
 
 
 
Table 8. 96-well plate layout for MS analysis of cell extracts. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A WT/LEU - Time point 0 min 
WT/LEU – Time 
point 10 min 
WT/LEU – Time 
point 30 min 
WT/LEU – Time 
point 60 min 
B WT/LEU – Time point 180 min 
         
C 
WT/Experimental 
label – Time point 
0 min 
WT/Experimental 
label – Time point 
10 min 
WT/Experimental 
label – Time point 
30 min 
WT/Experimental 
label – Time point 
60 min 
D 
WT/Experimental 
label – Time point 
180 min 
         
E 
Experimental 
condition 1 – Time 
point 0 min 
Experimental 
condition 1 – Time 
point 10 min 
Experimental 
condition 1 – Time 
point 30 min 
Experimental 
condition 1 – Time 
point 60 min 
F 
Experimental 
condition 1 – Time 
point 180 min 
         
G 
Experimental 
condition 2 – Time 
point 0 min 
Experimental 
condition 2 – Time 
point 10 min 
Experimental 
condition 2 – Time 
point 30 min 
Experimental 
condition 2 – Time 
point 60 min 
H 
Experimental 
condition 2 – Time 
point 180 min 
         
 
Result analysis 
96-well plates were analyzed via orbitrap mass spectrometer. The protocol was carried out in 
collaboration with Agios Pharmaceuticals and has been described in literature previously55. 
3.2 SPEIFIC AIM 2: RESULTS 
3.2.1 An IVD deficient cell line produces acetylcarnitine from LEU  
Specific Aim 2 was to characterize metabolic channeling through the BCAA pathways. Here, I 
focused on flux through the branched chain amino acid pathways in fibroblast cell lines derived 
from controls and patients with genetic disorders in the pathway (Table 8). These experiments 
were performed in collaboration with scientists at Agios Pharmaceuticals. First, wild type or 
mutant cells were grown in media supplemented with 13C,15N isotopes of LEU, ILE, or VAL for 
0, 10, 30, 60, and 180 min. The reactions then were quenched and washed with ammonium 
carbonate, and cellular lysates were extracted at -80 oC with 80/20 MeOH/H2O. As a control, 
cells were grown with 13C,15N labeled LEU for every experimental run. All samples were 
lyophilized then sent to Agios for metabolite analysis by tandem mass spectrometry. Figure 19 
shows results from wild type and IVA cell lines grown in labeled LEU. As expected, 
isovalerylcarnitine accumulated in the IVD deficient but not wild type cells. In contrast, the IVD 
deficient cells show a small accumulation of acetylcarnitine, the end product of LEU catabolism, 
compared to wild type cells. Since the IVD deficient cell line had a null 149 G>C mutation56 
shown to have no immune-detectable IVD protein, production of any end-product is unexpected. 
This result indicates alternative metabolism of the labeled isovaleryl-CoA from LEU, a potential 
sign of low level metabolic cross-correction by one of the other BCAA catabolic pathways.  
 
 Figure 19. IVD cells fed labeled LEU show labeled end-product. 
The red line represents the WT cell line and the blue line represents the IVA patient derived cell 
line. The vertical axes measure the corrected percentage of the acetylcarnitine pool derived from 
the label. As described in the text, any amount of acetylcarnitine accumulation in the IVD cell is 
of significance due to its null mutation. 
 
3.2.2 SBCAD and IBD deficient cell lines generate propionylcarnitine from ILE and VAL  
To examine metabolic flux through the ILE and VAL pathways, IBD and SBCAD deficient cell 
lines were grown in stable isotope labeled VAL and ILE, respectively, as in the previous section 
(Figure 20). The IBD cell line contained a mutation at 455T>C and the SBCAD cell line 
contained a mutation at 443C>T. The mutations in both patient cell lines caused complete 
deficiency in the enzyme57,58. When SBCAD deficient cells were grown in labeled ILE, ~15% of 
the total propionylcarnitine pool was derived from the labeled ILE (Figure 20A). In all 
experiments performed, labeled substrate was added to 50% enrichment. For example, standard 
DMEM media contains 0.8 mM of LEU, so to test BCAA metabolics and increase flux, 0.8 mM 
13C,15N-labeled LEU was added to the media. Thus, the effecive percentage of labeled end 
product seen in Figures 20 and 21 can be doubled due to the 50% enrichment of the label. When 
IBD cell lines were grown in labled VAL, 2% of the cellular propionylcarnitine was derived 
from the labeled VAL (Figure 20B). Again, this number can effectively be doubled to represent 
the amounts of VAL derived propionylcarnitine. When a WT cell line was grown in the presence 
of labeled ILE, >20% of the propionylcarnitine pool was labeled (Figure 21), incidating that a 
large proportion of the cellular propionate pool derives from ILE.  
 
 Figure 20. SBCAD cells fed labeled ILE and IBD cells fed labeled VAL produces labeled 
propionylcarnitine. 
 
The black and gray lines represent the amount of 12C propionylcarnitine in the cullular extract, 
and the blue lines respresent the 13C propionylcarnitine in the extract derived from the added 
label. As noted in the text, ILE appears to be a larger propiogenic metabolite of the BCAAs than 
VAL. 
 
 Figure 21. BCAA contributors to labeled propionylcarnitine. 
Individual contributors of propionylcarnitine. Labeled BCAAs were added to HFF-1 cells and 
fraction of propionylcarnitine pool derived from the labeled was analyzed. ILE is a higher 
contributor to propionylcarnitine than VAL. 
3.2.3 Propiogenic metabolites contribute differently to the propionyl-CoA pool 
These results suggest that each of the popiogenic amino acids contribute differentially to the 
intracellular propionate pool, an issue of importance when considering dietary management of 
patients with propionic and methylmalonic acidemias. To further examine this issue, wild type 
cells were separately cultured in media supplemented with universally labeled VAL, MET, ILE, 
or THR, and accumulation of propionylcarnitine was measured. The cells were also grown in the 
presence of labeled 13C3-5,6,7-heptanoic acid, another propiogenic compound. Figure 22 shows 
the accumulation of propionylcarnitine obtained with each labled substrate. Labeled VAL, MET, 
and THR produce little to no measurable propionylcarnitine. The major contributors to the 
propionate pool were ILE and the C7 fatty acid, a result that could impact the treatment of 
patients with propionic and methylmalonic acidemias. Note that the 0 min time points for VAL 
and THR showed a non-zero accumulation of labeled propionyl-carnitine accumulation, which is 
imposible as no label was added to the cells for this time point. The amount of label generated in 
the 0 min time point was then subtracted from the remaining time points, hence a negative 
accumulation of labeled proionylcarnitine.  
 
 
Figure 22. Differential contributions from propiogenic substrates to the propionylcarnitine pool. 
Vertical axis represents the percent of total propionylcarnitine in WT cells that is derived from 
the labeled substrate. As seen above in Figure 21, ILE contributes the most to propionylcarnitine. 
Heptanoic acid also plays a role in the generation of propionylcarnitine, but the remaining 
substrates exhibit zero accumulation of the propionylcarnitine. 
 
3.3 DISCUSSION 
Specific aim 2 took a different approach to identify interaction of BCAA enzymes: looking for 
evidence of functional cross talk across metabolic pathways. These experiments took advantage 
of the availability of cell lines with deficiencies in IVD, SBCAD, and IBD. In these cells, 
production of the bona fide end product of catabolism, when metabolism of the precursor amino 
acid pathway is blocked, suggests shunting to another pathway. Thus, the production of labeled 
end products seen in these experiments is significant, suggesting that the alternative enzymes are 
physically close enough to allow reaction with the other promiscuous ACADs. For example, 
since 15% of the propionylcarnitine in SBCAD cell lines incubated with labeled ILE is labeled, it 
seems likely that the labeled, blocked 2-methylbutyryl-CoA is being acted upon by IVD or, more 
likely based on substrate specificity, IBD. Direct channeling of substrates is much more 
energetically favorable than catching and releasing substrates, especially sub-optimal ones; and, 
therefore, lends credence to the hypothesis of a BCAA protein complex encompassing at least 
the ILE and VAL pathways. As a much lower amount of label from LEU finds its way to 
acetylcarnitine, the IVD metabolon may be distinct form the ILE/VAL one, consistent with 
findings from Specific Aim 1. As described in the previous section, STED imaging would help 
to confirm this conclusion.  
Of note, the flux experiments demonstrating that ILE and C7 dominate the contribution to 
the propionate pool have immediate potential clinical relevance. Patients with propionic and 
methylmalonic acidemias are treated with harsh dietary restrictions of VAL, MET, ILE, and 
THR as a means to reduce propionyl-CoA production. Since ILE contributes to the propionyl-
CoA pool by ~10 fold over VAL, THR, and MET, patients likely need only to be restricted of 
ILE, simplifying their dietary management. One unanswered question remains the fate of 
propionyl-CoA generated from VAL, MET, and THR. This question is explored in Future 
Directions below. 
4.0  A NOVEL TREATMENT FOR PROPIONIC ACIDEMIA 
4.1 INTRODUCTION 
The focus of this chapter shifts from the BCAA ACADs discussed previously to PPA/MMA. As 
noted above, PPA and MMA affect approximately 1:100,000 patients each in the US. This 
number is increased in Chinese populations, and a visiting scholar, colleague, and collaborator, 
Dr. Bingjuan Han has focused her prior clinical work on the treatment of propionic and 
methylmolonic acidemia patients in China. Together with Dr. Han, the experiments performed in 
this section explored options for more effectively treating PPA. Current treatments rely largely 
on dietary restriction and liver transplantation with varying results. Given the loss of propionyl-
CoA into the TCA cycle in this disorder, along with evidence of mitochondrial energy 
dysfunction, anaplerotic therapies, a supplantation of the TCA cycle, is a logical therapy. As seen 
in Figure 5, a block in PCC or MUT results in a loss of succinyl-CoA and subsequently succinate 
in the TCA cycle, reducing substrates for energy production, and increasing cellular stress.  
Experiments in this section explore treatment of propionic acidemia fibroblasts with 
succinate as an anaplerotic agent and a cardiolipin binding peptide (CLBP) to act as a 
stabilization agenet of the inner mitochondrial membrane. CLPB is a proprietary molecule 
modeled on elamipretide currently used in clinical trials for treatment of respiratory chain defects 
and Barth syndrome59. This compound targets the mitochondria and stabilizes the repiratory 
chain super-complex by interacting with the cardiolipin critical for inner mitochondrial 
membrane structure. The peptide has also been shown to act as an antioxidant and reduce ROS 
species in the mitochondria60. The CLBP could provide benefit to patients with PPA and MMA 
as both disorders have been proposed to induce mitiochondrial dysfunction.  
4.2 MATERIALS AND METHODS 
Materials 
Protease inhibitor  – Life Tech; Cat#11836153001; 1 tablet/1 mL H2O to obtain 10X  
 
RIPA buffer  – Thermo Fisher; Cat#89901; 1 mL RIPA buffer + 100 µL 10X protease 
inhibitor 
 
MitoSox  – 1 vial (50 µg) + 13.6 µL anhydrous DMSO = 5 M master solution; 
experimental concentration = 5 µM 
 
MitoTracker  – 1 vial (40 µg) + 74.4 µL anhydrous DMSO = 1 mM master solution; 
experimental concentration = 0.15 µM  
 
Sodium succinate  – Sigma Aldrich; Cat#S2378 
 
Cardiolipin binding peptide – proprietary molecule based on elamipretide 
 
Glucose-free media  – 50 mL FBS + 5 mL L-glutamine + 5 mL penicillin/streptomycin; life 
Technologies; Cat#11966-025 
 
 
Whole cell lysate 
WT, PPA, and MMA cell lines were grown in culture. PPA and MMA61 cell lines were obtained 
from patients with a molecularly confirmed diagnosis. The cell culture protocol for detaching an 
adherent monolayer of cells was followed and a pellet was made from the detached cell 
suspension. The pellet can be stored at -80 oC. Pellet was re-suspended with 150 µL of cold 
RIPA buffer (including protease inhibitor – see above). The samples stood on ice for 30 min, 
vortexing every 10 min. The resulting mixture was centrifuged at 14,000 xg for 15 min at 4 oC. 
Supernatant (lysate) was transferred to new vial for analysis on western blots. Traditionally, the 
Vockley lab uses < 20 µg of protein per lane for western blot visualization. Lysate can be stored 
in -80 oC for long-term. 
 
MitoSox/MitoTracker 
From a 90% confluent T25 flask of fibroblasts, cell pellet was harvested for analysis by 
trypsinizing as described above, and cells/trypsin were suspended in 5 mL media. Samples were 
centrifuged at 500 xg for 6 min. The supernatants were removed, and the pellet was re-suspended 
in 850 µL complete DMEM media. Using a 1:10 dilution, cells were counted while preparing 
MitoSox and MitoTracker as listed above in “Materials.” 45,000 viable cells were taken and 
suspended in media to make 200 µL of cell sample. 100 µL of MitoSox/MitoTracker master mix 
was pipetted to samples and incubated at 37 oC for 20 min in 4 replicates. After incubation, cells 
were analyzed with via flow cytometry. 
4.3 SPECIFIC AIM 3: RESULTS 
4.3.1 Cardiolipin binding peptide decreases ROS production and mitochondrial mass in 
fibroblast PPA cells 
Wild type, MMA, and PPA cells were grown in culture without glucose to increase reliance on 
oxidative phosphorylation for energy, supplemented to 4 mM succinate for 24 hrs, and cells were 
harvested and assessed for reactive oxygen species and mitochondrial mass as a mesaure of 
cellular stress. Cells were counted, and incubated with MitoSox Red to measure reactive oxygen 
species and MitoTracker Green  to measure mitochondrial mass in four replicates. Cells from a 
patient with PPA but not MMA showed an increase in ROS (Figure 23). Cells treated with 
succinate showed no statistically significant change in ROS production or mitochondrial mass 
(Figure 24). The PPA cells upon treatment with succinate for 24 hrs do show a statistically 
significant increase in ROS, suggesting persistant damage to the electron transfer chain.  
Wild type, MMA, and PPA cells were grown again in culture without glucose, incubated 
with 100 nM cardiolipin binding peptide dissolved in DMEM media for 24 hrs, and cells were 
harvested and assessed for measurement of reactive oxygen species and mitochondrial mass. 
Incubation of cells with 100 nM CLBP reduced the levels of ROS in the PPA cell line, but not 
the MMA cell line (Figure 25). Similarly, CLBP treatment reduced the mitochondrial mass in 
PPA cells (Figure 26). Mitochondrial mass was near normal in MMA cells and did not change 
upon treatment with CLBP.  
 Figure 23. PPA experiences elevated ROS and mitochondrial mass as a marker for cellular stress. 
MMA cell lines exhibited slightly elevated mitochondrial mass and ROS production, but not to 
significant levels. Colored bars represent means of four technical replicates for each cell line. 
Error bars represent standard error. Statistical significance determined by two-tailed t-test on all 
four sample replicates where p < 0.05 is considered significant as indicated by *s. 
 
 Figure 24. Succinate does not effectively decrease markers of cellular stress. 
The dark shaded bars labeled with “S” in this graph represent the cell lines being treated with 4 
mM of succinate for 24 hrs. MitoSox measures ROS, and MitoTracker measures mitochondrial 
mass. None of the changes between non-treated and treated cells seen were statistically, 
significantly decreased. Colored bars represent means of four technical replicates for each cell 
line. Error bars represent standard error. Statistical significance determined by two-tailed t-test 
on all four sample replicates where p < 0.05 is considered significant as indicated by *s. 
  
Figure 25. ROS production by cardiolipin binding peptide in PPA cells. 
Again, dark bars labeled with “C” represent treatment of the cells for 24 hrs with the cardiolipin 
binding peptide. ROS production was elevated in PPA which was reduced to near normal when 
treated with CLBP. MMA ROS was not elevated. Colored bars represent means of three 
technical replicates for each cell line. Error bars represent standard error. Statistical significance 
determined by two-tailed t-test on all three sample replicates where p < 0.05 is considered 
significant as indicated by *s. 
 
 Figure 26. Mitochondrial mass reduced by cardiolipin binding peptide in WT and PPA cells. 
Following the same pattern as seen in the previous two figures, note the statistically significant 
reduction in mitochondrial mass in both WT and PPA cell lines under the treatment of CLBP. 
Colored bars represent means of four technical replicates for each cell line. Error bars represent 
standard error. Statistical significance determined by two-tailed t-test on all four sample 
replicates where p < 0.05 is considered significant as indicated by *s. 
 
4.3.2 Cardiolipin binding peptide increases PCC amount in PA fibroblasts 
Wild type, PPA and MMA cells were grown in glucose free media to stress the cells and increase 
use of alternative energy sources such as BCAAs. Succinate or the cardiolipin binding peptide 
(CLBP) was then added directly to the cellular growth media and cells were grown for 24 hours. 
Cells were harvested, lysates were electrophoresed on SDS-PAG gels, and the gels were 
transferred to PVDF membranes. PCCA and MUT proteins were visulized with streptavidin and 
a MUT specific atibody. (Note that streptavidin was used to visualize PCCA based on its strong 
avidity to biotin, a cofactor of PCCA. The streptavidin used in this experiment was directly 
conjugated to a fluorophore for western blotting.) Figure 27 shows that PCCA is decresed in the 
PPA cells compared to wild type, and that MUT is completely absent in the MMA cells. 
Succinate alone did not increase the level of PCCA or MUT. In contrast, cells incubated with 
CLBP showed increased PCCA, while MUT was unaffected.  
  
 
Figure 27. Western blot of succinate and cardiolipin binding peptide treatments. 
Note that the streptavidin blot shows two bands in close proximity. The top band is that of 
MCCC1 of the LEU pathway which also utilizes biotin. The bottom band is of more interest in 
this context as it represents the PCCA subunit that is deficient in PPA patients and in this patient-
derived cell line. 
 
4.4 DISCUSSION 
Elamipretide, an analogue of the CLBP used in these experiments, has been shown to interact 
with the inner mitochondrial membrane and stabilize mitochondrial respiratory chain 
supercomplexes. Stabilization of PCC in the PPA cells by the CLBP suggests that the PCC may 
also be part of a BCAA protein complex interacting with the mitochondrial membrane, 
consistent with findings in the previous two aims. These results, taken with those found in 
section 3, highlight a possible novel approach to PPA theraputics. Treatment with with fewer 
dietary amino acid restrictions (only ILE), along with addition of the CLBP to reduce the 
induction of secondary ROS, could provide better therapy to these patients. More studies will 
need to be performed to validate this novel treatment including measurement of cellular oxygen 
consumption rates, and animal model testing such as a labeled metabolic flux study.  
5.0  OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
The main conclusion of this thesis, is that branched chain amino acid metabolism likely occurs in 
one or more multi-protein complex(es) that promotes metabolic channeling. It would appear that 
mitochondria have developed multiple protein complexes that enhance metabolic channeling. 
This phenomenon is seen in the electron transport chain (ETC) which is organized into a super-
complex for energy production. My results support the hypothesis that BCAA catabolism 
enzymes likely form two substrate-channeling, energetically-favorable protein complexes in the 
mitochondria, one for LEU catabolism and one for ILE and VAL. This finding may help explain 
the disparate symptoms seen in IVA vs isobutyryl and 2-methylbutyryl academia. In the case of 
IVA, the lack of another closely associated metabolon allows the isovaleryl-CoA accumulating 
behind the metabolic block to escape into the mitochondrial matrix and cause damage via 
interaction with other metabolic enzymes. In contrast, the metabolic consequences of SBCAD 
and IBD deficiencies, by virtue of close proximity to each other, could be abrogated by 
utilization of the alternate ACAD and return of the product to the appropriate pathway beyond 
the metabolic block. The known substrate promiscuity of SBCAD and IBD, and their utilization 
of each other’s substrate relatively efficiently are consistent with this possibility. Interestingly, a 
recent study62 reports that IVD shows a relatively high affinity for 2-methylbutylryl-CoA (Km = 
1.9 µM). This finding lends credit to my hypothesis that a build-up of 2-methylbutyryl-CoA 
causes insignificant metabolic changes due to substrate sharing by BCAA ACADs. In this case, a 
block in catabolism of 2-methylbutyryl-CoA could be abrogated by IBD accepting the nearby 
metabolite in a larger shared ILE/VAL super-complex or by IVD accepting a released metabolite 
in its own LEU protein complex. Secondary disruption of the LEU catabolic complex by primary 
mutations in one protein of the complex may also play a role in the pathogenicity of IVA. Here, 
mutations that might leave some residual activity in the IVD protein could still lead to disruption 
of its interaction with other complex member proteins and ultimately lead to a more severe 
phenotype than predicted by the effect of the mutation on IVD activity alone. To test this 
hypothesis, one could use patient derived cell lines of varying genotypes and repeat the 
experiments presented in this dissertation. If the hypothesis of a LEU pathway metabolon is true, 
one would expect the more severe mutations in IVD based on patient reports to have significantly 
less co-localization with other BCAA enzymes than a WT counter-part. A less-severe, or 
asymptomatic patient-derived IVA cell line identified through newborn screening may show a 
similar amount of co-localization of IVD with proteins like 3MCC or the BCKDH complex as 
compared to controls. Alternatively, expression of mutations in prokaryotic systems would allow 
demonstration of both activity and stability. Mutations affecting both could lead to secondary 
disruption of a protein complex, while a stable protein might lead to milder symptoms due to 
preservation of protein interactions in the complex. Thus, knowledge of the interactive 
architecture of these proteins in the mitochondria would be useful help predict disease severity. 
If patient cell lines are not available, modern technologies like CRISPR could be used to create 
cellular models for analysis. Using CRISPR technology, various disease-causing mutations can 
be simulated in WT cells. They could then be analyzed for protein-protein interactions by 
western blotting, proteomic analysis, or STED imaging as for patient cell lines.  
My studies show that mutations in the PPA genes lead to accumulation of ROS and that 
these can be reduced by treatment with a mitochondrial targeted antioxidant. Consistent with this 
finding, literature studies have reported abnormalities in mitochondrial structure and oxidative 
phosphorylation. However, there is currently no viable explanation for why this should occur. 
My results offer one possible solution. The Vockley lab has shown that enzymes of fatty acid 
oxidation and ETC form a physical complex and that mutations in FAO proteins lead to 
secondary disruption of oxidative phosphorylation and the accumulation of ROS. Based on my 
results, I predict that the ILE/VAL metabolic complex interacts with the inner mitochondrial 
membrane in close approximation to the ETC and TCA cycle in order to promote efficient 
delivery of propionyl-CoA for energy metabolism. Disruption of such a complex, would 
destabilize the ETC, and provide one possible pathophysiologic mechanism increased ROS 
production seen in PPA cells. Stabilization of oxidized cardiolipin by the CLBP would be 
predicted to stabilize the inner mitochondrial membrane, and thus the ILE/VAL metabolic 
complex and ETC super-complexes. If this is the case, further STED imaging studies could be 
performed to analyze a potential interaction between distal members of ILE/VAL catabolism and 
members of the TCA cycle. To explore this angle further, one could perform STED imaging 
experiments with and without the treatment of CLBP in the cellular monolayer. An increase in 
co-localization of BCAA enzymes as well as an increase in co-localization between BCAA 
enzymes (like PCC and MUT) with TCA cycle or ETC super-complex enzymes would be 
supportive of important in vivo interactions.  
Propionyl-CoA is a critical end product of ILE and VAL metabolism, necessary to make 
succinyl-CoA for the TCA cycle and ETC. The metabolic flux studies performed as part of 
specific aim 2b led to the relatively surprising discovery that different propiogenic substrates 
contributed differentially to the propionylcarnitine pool in cells. Thus, while VAL, MET, ILE 
and THR are all metabolized at least in part to propionyl-CoA, only the propionyl-CoA from ILE 
contributes significantly to cellular propionylcarnitine pool. Propionyl-CoA from the other 
amino acids, presumably find another metabolic destination. This finding has significant clinical 
implications, namely, that in patients with PPA or MMA, only ILE needs to be restricted in the 
diet, making dietary management of these patient much easier. As a secondary implication, 
clinical studies of patients with long chain fatty acid oxidation defects demonstrate a secondary 
deficiency of the TCA cycle (Figure 5) that is readily reversed by supplementation with odd 
chain carbon substrates63. One might consider BCAAs as an alternate source of TCA cycle 
intermediates; however, preliminary data by my collaborators at Agios Pharmaceuticals shows 
that propionyl-CoA derived from labeled ILE does not efficiently enter the TCA cycle (Figure 
28). In this experiment, WT human foreskin fibroblast (HFF1) cells were cultured in media 
containing stably labeled 13C BCAAs. One would expect the incorporation of a BCAA such as 
ILE to readily enter the TCA cycle through succinyl-CoA; however, little to no 13C labeled 
malate was detected via MS/MS. This suggests that BCAAs are likely an inadequate treatment 
for fatty acid oxidation disorders (FAODs). 
 
 Figure 28. Labeled malate observed upon addition of labeled ILE to WT HFF1 cells. 
Of the total measurable malate in the HFF1 cells, little to no labeled metabolite is detected, 
indicating that propionyl-CoA from ILE does not readily enter the TCA cycle. 
  
 
Additional experiments are necessary to determine the fate of propionyl-CoA derived 
from catabolism from VAL, MET, or THR. To test this, cells could be grown in the presence of 
various labeled amino acids, followed by an analysis by un-targeted metabolomics. I would 
expect to see an accumulation of labeled propionyl-CoA only in cell lines treated with labeled 
ILE. Cells treated with VAL, MET, and THR would be more enigmatic, though intermediate 
metabolites in each of their respective catabolic pathways should be explored to investigate the 
potential for shunting of these metabolites into other pathways. Additionally, an animal model of 
PPA or MMA would be useful in studying this hypothesis. Feeding the animals different diets 
restricted in different combinations of the four labeled “propiogenic” amino acids, followed by 
metabolomics analysis as described for cellular experiments would provide additional insight 
into the fate of propionyl-CoA derived from each amino acid. 
While my experimental results are consistent with the presence of one or more BCAA 
protein complexes, technology has been a major limiting factor. The BCAA metabolic 
complexes appear to be very labile and were difficult to manipulate in vitro. This problem 
minimized the utility of cross linking and gel electrophoresis experiments. Thus, I eventually 
switched to a technique that could interrogate interactions in situ to minimize the effect of 
complex instability. In this context, STED generated the most compelling direct evidence of 
interactions of IVD and 3MCC but not IVD and SBCAD. Unfortunately, lack of availability of 
appropriate antibodies for these studies limited a more comprehensive exploration of other 
complex members. As additional antibodies become available, further STED analysis will be 
possible. Other techniques to directly visualize protein interactions could also be explored. One 
such technique, immune-electron microscopy, could map the molecular architecture of the 
BCAA enzymes, potentially using antibodies that were unsuccessful with STED. The lack of 
stability of BCAA protein complex suggests that it is fluid, i.e., it is not held rigidly in place in 
the mitochondria, and/or its protein components can change with time. Exploring additional 
methods to better stabilize this super-complex would allow more robust co-immunoprecipitation 
proteomic experiments. Finally, it is important to note the limitation of a dearth of patient 
samples. The branched chain organic acidurias are rare, and a large bank of patient derived cell 
lines is not available. This was especially true for MMA patient derived cell lines in section 4 
above. I had access to two MMA cell lines, but their growth potential and response in metabolic 
experiments was limited by a high passage number. Once again, gene editing technologies may 
prove to be crucial to generate appropriate experimental material. Additionally, the study of 
more wild type samples will allow assessment of the natural variations in super-complex 
formation or metabolic flux. 
In conclusion, this thesis provides evidence for the presence of a fluid interaction of the 
enzymes of BCAA into one or more functional protein complexes that likely interacts with the 
inner mitochondrial membrane. Further, evidence is provided that the contribution of the 
propiogenic amino acids into the cellular propionylcarnitine pool is unequal and is dominated by 
ILE. In total, these results provide the opportunity for direct patient benefit by directing 
development of drugs that improve complex stability and/or abrogate the mitochondrial 
derangements induced by the lack of complex stability, as well as providing better guidance for 
the dietary management of disorders of propionate metabolism.  
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